Lycia Therapeutics

To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.